News

May 5th 2020 TAGCyx raises approximately 200 million JPY

TAGCyx Biotechnologies, Inc. (Tokyo, Japan) has raised approximately 200 million JPY from UTokyo Innovation Platform Co., Ltd. (Tokyo)

TAGCyx is developing unique DNA aptamer called “Xenoligo®” in healthcare field, using proprietary artificial nucleic acid base pair technology. Aptamers, also known as “chemically synthesizable antibodies,” are oligo nucleic acids (DNA or RNA) and peptides that bind to specific molecules, and act like antibody antigen interaction. Xenoligo® has following features. ① high binding affinity to proteins by particular hydrophobic interaction of artificial bases (you can select a high binding candidate molecule from a huge DNA library of 1014 or more that can be randomly generated), ② stabilization by proprietary Mini-hair pin technology (realization of sufficient stability as a drug), ③ low manufacturing cost (it can be manufactured by chemical synthesis unlike antibody drugs), and ④ high versatility (applicable to targets that antibody drugs are difficult to target).

Based on the platform technology of Xenoligo®, TAGCyx has concentrated management resources in the drug discovery business since 2016, and through multiple steps of financing, has entered into several collaboration agreements with pharmaceutical and healthcare companies. Achieving this funding, TAGCyx will accelerate R&D for changing paradigm to human healthcare.

Feb 19th 2020 TAGCyx and GC Pharma has entered into collaborative research and development for conducting various pre-clinical studies of TAGX-0004

February 19 2020: TAGCyx and GC Pharma (formerly known as Green Cross Corporation) has entered into collaborative research and development for conducting various pre-clinical studies of TAGX-0004.

TAGCyx has signed Joint Research and Development Agreement with GC Pharma (KRX: 006280) in relation to pursuing various pre-clinical studies of TAGX-0004, an anti-human vWF DNA aptamer containing proprietary artificial nucleotide.

TAGCyx has invented artificial nucleic acid base pair technology that enables to produce high affinity and selective DNA aptamers “Xenoligo®”, that is regarded to be an alternative to antibody therapeutics.

 

GC Pharma is a biopharmaceutical company that delivers life-saving and life-sustaining protein therapeutics and vaccines. Headquartered in South Korea, GC Pharma is the largest plasma protein product manufacturer in Asia and has been dedicated to quality healthcare solutions more than half a century.

 

TAGX-0004 is an innovative DNA aptamer therapeutics developed by TAGCyx aiming to treat thrombotic disorders such as brain and cardiac infarction, and currently under development for rare disease called acquired thrombotic thrombocytopenic purpura (aTTP).  TAGCyx has accumulated many pharmacological data to date in collaboration with a Japanese leading scientist in the field, Professor Masanori Matsumoto, Nara Medical University.

 

Dr. Chizuko Koseki, Chief Executive Officer of TAGCyx added “Together with GC Pharma, we believe our aptamer will be a key therapeutic option for the patient of aTTP, and eventually for other thrombotic diseases. GC Pharma’s deep insight will realize TAGCyx’ mission to provide an effective treatment to various challenging diseases”.

 

Under the agreement, GC Pharma will fund the development cost for pre-agreed pre-clinical studies, and TAGCyx will conduct the studies with CROs. Under the confidentiality of the agreement, further detail of the research is not disclosed.

 

December 25th 2019 TAGCyx receives milestone payment for collaborative research with HEALIOS K.K.

TAGCyx is pursuing collaborative research with HEALIOS K.K. (CEO: Hardy TS Kagimoto, MD, Head office: Tokyo, listed on Tokyo Stock Exchange Mothers Index: 4593) to generate innovative DNA aptamers for use in regenerative medicine using TAGCyx’ proprietary Xenoligo® platform. We are pleased to disclose that we have reached a milestone in the collaboration and received the relevant milestone payment.

Due to confidentiality obligations in our agreement with Healios, further details are not disclosed.

October 10th 2019: TAGCyx enters into a collaborative aptamer glycosylation research agreement with GlyTech, Inc.

TAGCyx has signed a collaborative research agreement with GlyTech, Inc. (CEO: Hiroaki Asai, Head office: Kyoto) in relation to glycosylation techniques for aptamer therapeutics.
TAGCyx possesses a leading, proprietary, artificial nucleic acid base pair technology, used to produce high affinity and selective “Xenoligo®” DNA aptamers, while GlyTech possesses a unique platform for the production of an extensive variety of highly purified human N-glycans, and the technology to attach them to a specific site on target molecules such as synthetic peptides.
Modifying Xenoligo® with GlyTech’s glycosylation technology is expected to increase the functionality of aptamers and add high value to them.

Dr Chizuko Koseki, Chief Executive Officer of TAGCyx added “We are pleased to enter into a collaboration with GlyTech, bringing together two leading technologies to potentially enhance therapeutics research”.